Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.46 - $0.65 $7,736 - $10,932
-16,819 Reduced 0.4%
4,225,820 $2.03 Million
Q2 2023

Aug 14, 2023

BUY
$0.57 - $1.08 $9,586 - $18,164
16,819 Added 0.4%
4,242,639 $2.55 Million
Q1 2023

May 15, 2023

BUY
$0.66 - $1.29 $12,276 - $23,994
18,600 Added 0.44%
4,225,820 $3.17 Million
Q4 2022

Feb 14, 2023

SELL
$1.1 - $2.45 $1.3 Million - $2.89 Million
-1,179,300 Reduced 21.89%
4,207,220 $5.22 Million
Q3 2022

Nov 14, 2022

SELL
$1.96 - $3.32 $2.08 Million - $3.53 Million
-1,062,500 Reduced 16.48%
5,386,520 $11.1 Million
Q2 2022

Aug 15, 2022

SELL
$2.27 - $4.86 $6.61 Million - $14.2 Million
-2,913,431 Reduced 31.12%
6,449,020 $17.9 Million
Q1 2022

May 16, 2022

SELL
$3.69 - $5.65 $9.2 Million - $14.1 Million
-2,492,700 Reduced 21.03%
9,362,451 $40.9 Million
Q4 2021

Feb 14, 2022

BUY
$5.37 - $7.07 $30.8 Million - $40.5 Million
5,732,500 Added 93.63%
11,855,151 $65.4 Million
Q3 2021

Nov 15, 2021

BUY
$5.54 - $7.51 $4.36 Million - $5.91 Million
786,748 Added 14.74%
6,122,651 $37.8 Million
Q2 2021

Aug 16, 2021

BUY
$7.78 - $11.4 $390,517 - $572,223
50,195 Added 0.95%
5,335,903 $45.4 Million
Q1 2021

May 17, 2021

BUY
$5.12 - $8.48 $11.3 Million - $18.7 Million
2,210,708 Added 71.89%
5,285,708 $41.8 Million
Q4 2020

Feb 16, 2021

BUY
$3.16 - $7.03 $3.4 Million - $7.56 Million
1,075,000 Added 53.75%
3,075,000 $17.9 Million
Q3 2020

Nov 16, 2020

SELL
$3.26 - $4.73 $4.76 Million - $6.91 Million
-1,461,093 Reduced 42.21%
2,000,000 $6.78 Million
Q2 2020

Aug 14, 2020

BUY
$1.58 - $4.63 $2.78 Million - $8.15 Million
1,761,093 Added 103.59%
3,461,093 $16 Million
Q4 2019

Feb 14, 2020

BUY
$2.25 - $3.07 $2.7 Million - $3.68 Million
1,200,000 Added 240.0%
1,700,000 $4.66 Million
Q3 2019

Nov 15, 2019

BUY
$2.67 - $3.65 $1.34 Million - $1.83 Million
500,000 New
500,000 $1.47 Million
Q3 2018

Nov 14, 2018

SELL
$1.45 - $6.15 $362,500 - $1.54 Million
-250,000 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$1.25 - $2.65 $312,500 - $662,500
250,000 New
250,000 $463,000
Q4 2017

Feb 14, 2018

SELL
$1.23 - $2.3 $359,936 - $673,051
-292,631 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$1.95 - $2.25 $570,630 - $658,419
292,631
292,631 $658,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.